We are developing targeted therapies for gastrointestinal cancer designed to address treatment resistance.
Approximately 80% of GIST cases are driven by mutations that activate the tyrosine kinase KIT, and the disease remains KIT dependent through successive lines of therapy. Most patients who receive first-line imatinib as a treatment for GIST experience disease progression due to the emergence of secondary KIT mutations.
Subsequent lines of kinase inhibitor therapy are significantly less effective. Our goal is to develop a truly pan-variant inhibitor that can address the limitations of current therapies.
We believe the broad inhibitory profile of THE-630 has the potential to generate robust and durable responses for advanced GIST patients across the spectrum of previously-treated patient populations.
We have submitted an IND for THE-630 with the U.S. Food and Drug Administration (FDA) and, if accepted, we plan to initiate a Phase 1/2 dose escalation and expansion clinical trial in patients with previously-treated GIST.